Novartis’ Shaw Pushing For U.S. Outcomes-Based Reimbursement
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. Country Head Christi Shaw talked in an interview about Novartis’ near-term growth drivers – namely the heart failure drug LCZ696 – and how Novartis is evaluating outcomes-based reimbursement models to address growing payer pressure in the U.S.
You may also be interested in...
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Mural Oncology Primed For IL-2 Readouts Next Year
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.